Ian Wilding, executive chairman of Nottingham, UK-based Pharmaceutical Profiles, celebrates receiving one of the pharmaceutical industry's major US awards
Frost and Sullivan's prestigious 2004 Excellence in Technology Award in the field of drug discovery and development has been awarded to Nottingham, UK-based Pharmaceutical Profiles for the company's pioneering efforts to enhance the adoption of innovative technologies in early phase drug development.
The award is only given to companies that have pioneered the development and introduction of innovative technology in the market - normally a technology that has either impacted or has the potential to impact several market sectors.
The award recognises successful technology development that is expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture.
It also recognises the overall technical excellence of a company and its commitment towards technology innovation.
Pharmaceutical Profiles says it is enjoying a very successful period, particularly in the United States.
Ever increasing interest in human drug absorption studies, using the proprietary Enterion drug delivery capsule, is helping the firm gain more and more new contracts for its early phase drug development trials and drug delivery technology teams. Since 2002, the company has undertaken more than 150 complex clinical studies for major pharmaceutical companies, drug delivery companies and biotechnology companies located in North America, Europe and Japan.
